Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Naresh G. Punwani"'
Publikováno v:
Journal of clinical pharmacology. 56(11)
Drug-drug interaction (DDI) studies involving warfarin are typically conducted with subtherapeutic doses of warfarin to ensure the safety of volunteers. However, this approach may potentially have a systemic bias of underestimating pharmacodynamic (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e79ff21a14653241926333b55c3afacd
https://pubmed.ncbi.nlm.nih.gov/26990117
https://pubmed.ncbi.nlm.nih.gov/26990117
Autor:
Naresh G. Punwani
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:363-365
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c061a1932ff65d918270e995cf29a0d7
https://doi.org/10.1016/j.clpt.2003.12.011
https://doi.org/10.1016/j.clpt.2003.12.011
Autor:
Xuejun, Chen, Jack G, Shi, Thomas, Emm, Peggy A, Scherle, Ryan F, McGee, Yvonne, Lo, Robert R, Landman, Naresh G, Punwani, William V, Williams, Swamy, Yeleswaram
Publikováno v:
Clinical pharmacology in drug development. 3(1)
Hepatic and renal impairment studies were conducted with ruxolitinib, a JAK12 inhibitor that is cleared predominantly by metabolism. Both studies were open label, single-dose studies. Ruxolitinib area under the curve (AUC) was increased by 87%, 28%,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f05fbccf01a1a3a08361431d95c4801
https://pubmed.ncbi.nlm.nih.gov/27128228
https://pubmed.ncbi.nlm.nih.gov/27128228